Over the past five years, the cosmetic industry has met with several legislative changes. Within the new legislative package, including the new REACH and CLP, it is important to find a comfortable routine that will minimize costs while staying effective and compliant with all regulations.
Patent protection, ergo, patient protection
Companies that want to be successful in this shifting legal environment need to understand that intellectual property and patenting practices are essential in facilitating the competitive advantage and revenue returns as much as the value perceived by the patient.
Learn how to rise to challenges such as patent and regulatory concerns, legal matters and drug registration in new emerging markets. Are you asking why and how? Let's cut this Gordian knot.
Patent rights are extended around the world through the WTO's Agreement on Trade–Related Aspects of Intellectual Property Rights (TRIPS), but the high death toll from infectious but curable and preventable diseases: the cost plus the availability of drugs and medication; legal and tax related issues; as well as poor health infrastructure profoundly affect the results.
According to Forbes research from 2013, the pharma industry generates higher profit margins than any other industrial sector, spends more on marketing than on research & development and continues to grow while still paying million–dollar fines for malpractice, illegal or wrong means of promotion, etc… To quote Bill Gates, “It's fine to celebrate success but it is more important to heed the lessons of failure.”
So, what are the main factors?
Inventors. Recognize the original creation of human intellect (IP–Intellectual Property) and the legal rights given to the creator to protect his invention for a certain period of time (IPR–Intellectual Property Rights).
Governments. Take legal steps to minimize the negative impact of parallel trade. Help poorer countries through innovative public–private partnerships (as the previously mentioned entrepreneur is doing in Africa with his Bill & Melinda Gates Foundation, the largest private foundation in the world).
Patients. No mercenary, lose the “I” and as with patents, think of the same general requirements: usefulness, transparency and novelty. Provide it all.
Companies need to understand property protection not only as a step towards the return of investment. What goes around comes around. Drive innovation and be awe–inspiring.
How successful are you in creating patient value, innovation and inspiration, and at the same time generating ROI?
Interested in this topic?
Advanced Protein Aggregation & Characterization
This training will focus on occurrence of particles in drug products, effects of protein aggregates, critical process and parameters. Attendees will gain overview of on utility and limits of predictive experiments, learn concerns from the authorities and relevant aggregation guidelines, and more.
CMC Analytical Comparability: Methods & Strategies for Biologics, Biosimilars & Biobetters
Attendees will be introduced to comparability in biosimilar development, the analytical strategies of protein characterization of biosimilars, the structure of proteins, in vitro pharmacology and much more.
Corporate Compliance & Transparency in the Pharmaceutical Industry
This two-day conference will serve as a platform for an open and dynamic dialogue with HCPs and patients to achieve common goals. Learn how to embed compliance in the business and develop one simple system for managing compliance & transparency in a complex and regulated environment.
Dr. Asma Ibrahim Al Mannaei, Director, Healthcare Quality Division | HAAD
Strategize your Risk Management Plan in 2 steps
Read below the interview with Judy to reveal the latest trends in risk management and find out what are the most important steps towards strategizing your risk management plan.
A prescription of Quality and Efficiency in the right doses
Read below the interview with Ronan to understand the importance of balance between quality and efficiency and reveal which pitfalls to avoid.